References

  1. Data on file. Neuronetics, Inc.
  2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration.
  3. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.
  4. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  5. Deng ZD, et al. (2013). Electric Field Depth-Focality Tradeoff in Transcranial Magnetic Stimulation: Stimulation Comparison of 50 Coil Designs. Brain Stimuli, 6(1):1-13.
  6. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  7. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  8. Gaynes BN, et al. (2008). Cleveland Clinic Journal of Medicine, 75(1):57-66.
  9. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516.
  10. Janicak PG, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.
  11. Kessler, RC et al. (2005). Arch Gen Psychiatry, 62(6):593-602.
  12. Liston C, et al. (2014). Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol Psychiatry, 76(7): 517–526.
  13. McDonald WM, et al. (2011). Improving the Antidepressant Efficacy of Transcranial Magnetic Stimulation: Maximizing the Number of Stimulations and Treatment Locations in Treatment-Resistant Depression. Depress Anxiety, 28:973-980.
  14. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  15. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216.
  16. Post A, et al. (2001). J Psychiatric Research, 35:193-215 6.
  17. Rush AJ, et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry, 163:1905–1917.
  18. Sackeim, HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  19. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40.
  20. American Psychiatric Association (2010). (eds: Gelenberg, AJ, Freeman, MP, Markowitz, JC, Rosenbaum, JF, Thase, ME, Trivedi, MH, Van Rhoads, RS). Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 3rd Edition.
  21. National Institute of Mental Health. US Department of Health and Human Services. Depression. https://www.nimh.nih.gov/health/statistics/major-depression.shtml.
  22. United States Census Bureau. https://data.census.gov.
  23. World Health Organization. Depression Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/depression.